Indivior (NASDAQ:INDV) Releases Quarterly Earnings Results, Hits Estimates

Indivior (NASDAQ:INDV) released its quarterly earnings data on Thursday. The company reported $0.32 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.32, Zacks reports. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Indivior updated its FY 2025 guidance to EPS.

Indivior Price Performance

Shares of INDV traded down $1.74 during midday trading on Thursday, reaching $9.17. The stock had a trading volume of 1,219,757 shares, compared to its average volume of 1,136,186. The company has a market capitalization of $1.26 billion, a P/E ratio of -231.42 and a beta of 0.73. The firm’s 50 day moving average price is $11.56 and its 200-day moving average price is $10.89. Indivior has a 52 week low of $7.33 and a 52 week high of $23.22.

Wall Street Analysts Forecast Growth

INDV has been the subject of several analyst reports. Rodman & Renshaw started coverage on Indivior in a research report on Tuesday, January 28th. They set a “buy” rating and a $16.00 price objective for the company. RODMAN&RENSHAW raised Indivior to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.